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Background: Staphylococcus aureus (S. aureus) is a major nosocomial pathogen that causes a variety of infections
and toxicoses. In recent years, the percentage of rifampicin-resistant S. aureus has increased rapidly in China. The
aims of this study were to analyze 1) the level of rifampicin resistance in S. aureus and its correlation with mutations
in the rpoB gene, and 2) the molecular characterization of rifampicin-resistant S. aureus isolates.
Results: 88 rifampicin-resistant S. aureus isolates were collected for this study. Of the 88 isolates, 83 (94.3%) were
high-level rifampicin resistant (MIC≥8 mg/L) while the remaining 5 isolates (5.7%) had a low-level resistance to
rifampicin (MIC, 2 to 4 mg/L). Four amino acid substitutions were found in the 88 isolates, which were 481His/Asn
(95.5%), 466Leu/Ser (87.5%), 477Ala/Asp (6.8%) and 486Ser/Leu (4.5%) respectively. All mutations were found to be
present in cluster I of the rpoB gene. The low-level resistant isolates were found to have only one mutation, while
the high-level resistant isolates had at least two or more mutations. The most common multiple mutations were
481His/Asn+466Leu/Ser(92.8%,77/83). The other multiple mutations found were 481His/Asn+477Ala/Asp (6.0%,5/83),
and 481His/Asn+466Leu/Ser+477Ala/Asp (1.2%,1/83). Out of 28 high-level rifampicin-resistant S. aureus isolates,
three molecular types were found, namely, ST239-MRSA-III-spa t030 (25/28, 89.3%), ST239-MRSA-III-spa t021 (2/28,
7.1%), and ST239-MRSA-III-spa t045 (1/28, 3.6%).
Conclusions: Rifampicin resistance in S. aureus was closely associated with mutations in the rpoB gene. High-level
rifampicin-resistant S. aureus is one of the most important features in Anhui Provincial Hospital, and high-level
rifampicin resistance in S. aureus is associated with multiple mutations of rpoB gene. The prevalence of high-level
rifampicin-resistant S. aureus in Anhui may be associated with the spread of the ST239-MRSA III-spa t030 clone.
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S. aureus is one of the most prevalent and clinically signifi-
cant pathogens worldwide, which causes a variety of
illnesses, ranging from minor infections of the skin to life-
threatening infections with bacteremia, endocarditis,
pneumonia and toxic shock syndrome [1]. With the
increased use of antimicrobial agents in health care set-
tings, multi-resistant S. aureus isolates have appeared and
become the most common cause of nosocomial and com-
munity infections around the world[2]. Vancomycin is one
of the selective drugs for MRSA infections. However,* Correspondence: xiaolingma@126.com
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reproduction in any medium, provided the orbecause of poor tissue diffusion and high toxicity, it is
often combined with rifampicin for deep-seated infections
such as osteomyelitis and endocarditis [3].
The frequency of the rifampicin-resistant (RIF-R) S.
aureus isolates have rapidly increased. In China, the per-
centage of RIF-R MRSA isolates was only 15.5% in 2004
and rapidly increased to 50.2% in 2008 [4]. However, no
information regarding the molecular mechanism of ri-
fampicin resistance in S. aureus has been available in
China. The objectives of the present study were to
analyze 1) mutations in the rpoB gene that contributed
to rifampicin resistance and 2) the molecular mechan-
isms of RIF-R S. aureus in Anhui Provincial Hospital.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Hospital setting
Anhui Provincial Hospital, which founded in 1898, is a
major regional hospital located in the capital of Anhui
Province. It is a nearly 1300-bed tertiary care teaching
centre. Anhui Provincial Hospital provides healthcare ser-
vices to patients from Anhui, Henan and Shandong pro-
vinces, and the average number of outpatients is about
two million per year. It is also the Affiliated Hospital of
Anhui Medical University and Anhui Province Medical
postgraduate training base of Shandong University.
Bacterial strains
Two hundred and eighty-three S. aureus were isolated
from clinical specimens in the Microbiology Department
of Anhui Provincial Hospital from January 2008 to
December 2008. Eighty-eight RIF-R S. aureus isolates
were re-identified by the disk diffusion method and used
for the present study. The RIF-R S. aureus isolates repre-
sented 31% of all S. aureus isolates in 2008. The origin
of the strains was mainly from respiratory samples and
also from blood cultures, catheter-related sites, Urine
samples, wound swabs, respiratory samples and exu-
dates. Oral informed consent was given by all patients
before taking the clinical specimen. The S. aureus iso-
lates were re-identified by Gram’s staining, microscopic
examination, coagulase testing and catalase testing.
MRSA was initially screened by the cefoxitin disk diffu-
sion method, and then confirmed by polymerase chain
reaction (PCR) detecting mecA.
Antimicrobial susceptibility testing
Two hundred and eighty-three S. aureus susceptibility to
penicillin (10 units), ampicillin/sulbactam (10/10μg), cefa-
zolin (30μg), vancomycin (30μg), erythromycin (15μg),
clindamycin (2μg), rifampicin (5μg), linezolid (30μg),
mupirocin (5μg), quinupristin/dalfopristin (15μg), tetracyc-
line (30μg), trimethoprim/sulfamethoxazole (1.25/23.75μg),
gentamicin (10μg), ciprofloxacin (5μg), and levofloxacin
(5μg) were determined by using the disk diffusion method
in accordance with standards recommended by the Clinical
and Laboratory Standards Institute (CLSI) [5]. Reference
strain ATCC25923 was used for quality control. MICs of
rifampicin for all S. aureus isolates were further deter-
mined by the agar dilution method[5], and S. aureus
ATCC 29213 and E.coli ATCC25922 were designated as
RIF-S and RIF-R controls, respectively. According to the
CLSI criteria[5], isolates were interpreted as RIF-S (MIC≤1
mg/L) and RIF-R (MIC≥4 mg/L) isolates.
Detection of rifampicin resistance-associated mutations
Total DNA from S. aureus was purified and used as a tem-
plate for amplification by PCR. An internal gene sequence
of 432 bp (nucleotides 1216 to 1648), was amplified byPCR. This region included the rifampicin resistance-
determining cluster I (nucleotides 1384–1464, amino acid
number 462–488) and cluster II (nucleotides 1543–1590,
amino acid number 515–530). The amplification was
carried out in 88 RIF-R strains. Amplification was carried
out as previously described [6]. The PCR products were
purified and analyzed by DNA sequencing. The nucleotide
sequences obtained were compared to the rpoB wild type
sequence from S.aureus subsp. aureus (GenBank accession




SCCmec typing of MRSA isolates was performed
using eight unique and specific pairs of primers for
SCCmec types and subtypes I, II, III, IV and V as described
previously [7].
Spa typing
The staphylococcus protein A (spa) variable repeat re-
gion from each MRSA isolate was amplified by simplex
PCR oligonucleotide primers as previously described
[8,9]. Purified spa PCR products were sequenced, and
spa types were assigned by using the spa database web-
site (http://www.ridom.de/spaserver).
Multilocus sequence typing (MLST)
MLST of MRSA isolates was conducted through amplifi-
cation of internal fragments of seven housekeeping
genes of S.aureus as described previously[10]. Following
purification and sequencing of these genes, allele quanti-
fication and sequence typing were assigned using a well-
characterized online database (http:// saureus.mlst.net/).
Results
Antimicrobial susceptibility patterns
Antimicrobial susceptibility testing by the disc diffusion
method revealed that all RIF-R S.aureus isolates were
MRSA and were resistant to β-lactam, ciprofloxacin,
erythromycin, levofloxacin, gentamycin and tetracycline.
Of the S.aureus isolates, 88.6% were resistant to clinda-
mycin. Isolates also displayed low levels of resistance to
sulfamethoxazole (9.1%), quinupristin (2.3%). There were
no vancomycin-resistant S.aureus isolates in our study.
Distribution of mutations associated with rifampicin
resistance
Among the 88 RIF-R MRSA isolates, 83 isolates showed
high-level rifampicin resistance (MIC ≥8 mg/L) and 5 iso-
lates showed low-level rifampicin resistance (MICs 2 to 4
mg/L)[3,11]. Four amino acid substitutions were found in
88 RIF-R isolates. Results are shown in Table 1. Mutation
at 481His/Asn was the most common and found in 95.5%
Table 1 The characteristics of the rifampicin-resistant S. aureus isolates studied






Rifampicin MIC Resistance pattern




TCA/TTA 486Leu/Ser 4 4.5% 4 4 CIP+E+GEN+TET(3)
CIP+E+GEN+TET+CC (1)
CAT/AAT 481His/Asn 1 1.1% 4 1 CIP+E+GEN+TET(1)





CAT/AAT+TTA/TCA 481His/Asn+466Leu/Ser 14 64 14 CIP+E+GEN+TET+CC (12)
CIP+E+GEN+TET+CC +SXT(2)
CAT/AAT+TTA/TCA 481His/Asn+466Leu/Ser 11 128 11 CIP+E+GEN+TET+CC (8)
CIP+E+GEN+TET+CC +SXT(3)
CAT/AAT+TTA/TCA 481His/Asn+466Leu/Ser 7 256 7 CIP+E+GEN+TET+CC +SXT(7)





1 1.1% 128 1 CIP+E+GEN+TET+CC (1)
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87.5% of isolates. The remaining mutations included
477Ala/Asp (6.8%) and 486Ser/Leu (4.5%). Five low-level
resistant isolates had only one mutation, while 83 high-
level resistant isolates had two or more mutations. The
single mutation 481His/Asn and 486Ser/Leu were confer-
ring low-level rifampicin resistance. Two mutations,
481His/Asn+466Leu/Ser, were the most common multiple
mutations found in 92.8% (77/83) of samples. The
remaining multiple mutated clones consisted of 481His/
Asn+477Ala/Asp (6.0%, 5/83) and 481His/Asn+466Leu/
Ser+477Ala/Asp (1.2% and 1/83, respectively).Molecular typing
SCCmec typing, MLST and spa typing were carried out
in the 28 high-level RIF-R MRSA strains. Results are
shown in Table 2. The majority (n =25, 89.3%) belonged
to a common molecular type, ST239-MRSAIII-spa t030.
The remaining molecular types were identified as
ST239-MRSA-III-spa t021 (2/28, 7.1%) and ST239-
MRSA-III-spa t045 (1/28, 3.6%).Table 2 Molecular features of 28 high-level rifampicin-resista
MLST (ST) SCCmec type spa-type Number of isolates Nucleotid
ST239 III t030 24 CAT/AAT+
1 CAT/AAT+
ST239 III t021 2 CAT/AAT+
ST239 III t045 1 CAT/AAT+
CIP, ciprofloxacin; E, erythromycin; CC, clindamycin; TET, tetracycline; SXT, sulfamethDiscussion
Multiresistance and high infection rates are common fea-
tures of S .aureus and are growing problems in hospital
settings. The high prevalence of antibiotic resistance in S.
aureus nosocomial isolates is currently explained by inten-
sive use of topical and systemic antimicrobial agents in
health care settings, which represents a highly selective
pressure for antibiotic-resistant bacterial clones [12]. In
particular, MRSA strains showed high resistance rates to
various antibiotics [13]. The proportion of MRSA isolates
has increased in recent years. In China, surveillance data
of bacterial resistance in 1998–1999 showed that the per-
centage of MRSA was 37.4% [14] and rapidly reached
51.7% in 2010 [4].
Rifampicin is an antibiotic of significant interest in the
rise of MRSA infections. A combination therapy, with an
antibiotic such as vancomycin often is required to reach
deep-seated infections effectively. Rifampicin acts by
interacting specifically with bacterial RNA polymerase
encoded by the gene rpoB [15]. Rifampicin resistance
emerges easily in S. aureus, in particular in methicillin-
resistant Strains [3].The prevalence of RIF-R MRSA hasnt S. aureus isolates
e mutation Amino acid substitution Resistance pattern
TTA/TCA 481His/Asn+466Leu/Ser CIP+E+GEN+TET(1)
CIP+E+GEN+TET+CC(23)
GCT/GAT 481His/Asn+477Ala/Asp CIP+E+GEN+TET+CC (1)
TTA/TCA 481His/Asn+466Leu/Ser CIP+E+GEN+TET+CC(2)
TTA/TCA 481His/Asn+466Leu/Ser CIP+E+GEN+TET+CC+SXT(1)
oxazole/trimethoprim; GEN, gentamycin; QD, quinupristin/dalfopristin.
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resistance rate. In China, the data obtained from the sur-
veillance of bacterial resistance showed that the percent-
age of RIF-R MRSA was 15.5% in 2004 and rapidly
reached 49.6% by 2006. The percentage remained high
from 2006 to 2009 [4]. Obviously, the nature of RIF-R
MRSA isolates represents a therapeutic challenge for
treating serious MRSA infections. Most RIF-R MRSA iso-
lates were high-level resistant in our study and the per-
centage was found to be 94.3%. In fact, it was higher than
the rate reported in some European countries, such as
Spain, which had a rate of 3.7% (4/108) in 2010 [6]. There
were two reasons that could explain the difference be-
tween the Rif-R rate in China compared to other coun-
tries. One possibility was the intensive use of some
antimicrobial agents in health care settings in China such
as quinolones, which not only could lead to the selection
of multi-resistant nosocomial isolates of S. aureus, but
also potentially induce endogenous, resistance-conferring
mutations in bacterial genes that encode drug targets. A
second possibility might be that the prevalence of MRSA
clones in China was different from European countries.
For a variety of bacteria, such as E. coli [16], Mycobac-
terium tuberculosis [17] and S .aureus [3], the main
mutations responsible for rifampicin resistance were in a
particular region encompassing a few hundred nucleo-
tides called the rifampicin resistance-determining region
(RRDR). In S. aureus the RRDR was divided into two
clusters which were designated cluster I (nucleotides
1384–1464, amino acids 462–488) and cluster II (nucleo-
tides 1543–1590, amino acids 515–530). As described in
previous studies, the two clusters were also both closely
associated with rifampicin resistance [3,18].
Here, we have amplified and sequenced portions of rpoB
from RIF-R S.aureus isolates. All four amino acid substitu-
tions we identified were present in cluster I. Mutation
481His/Asn was the most prevalent one. The majority
(n = 84, 96%) of the 88 RIF-R MRSA isolates harbored the
amino acid substitution 481His/Asn, which was in line
with previous reports [3,19]. Our results further confirm
that 481His/Asn has a major impact on the occurrence
and development of rifampicin resistance in S. aureus.
High-level rifampicin resistance may also be attributed to
additional mutations within rpoB, as previously described
[20]. The additional mutations we found were 466Leu/Ser
and 477Ala/Asp. Isolates containing multiple mutations,
481His/Asn and 466Leu/Ser,were reported by other stud-
ies, which also showed high-level rifampicin resistance
[18,19]. Mutational changes at amino acid position 477
have also been reported by several groups [3,6,18], but the
mutation rate was low and the types of amino acid substi-
tutions which arose were different.
MRSA infections have been caused by a relatively
small number of epidemic MRSA clones. As describedin previous studies, the two major epidemic MRSA
clones identified in China from 2005 to 2006 were
ST239-MRSA III and ST5-MRSA II [21]. A pandemic
MRSA clone ST239, which was found to be derived
from ST8 and ST30 parental strains through simple
chromosome replacement instead of movement of mo-
bile genetic elements, was first found in Brazil and
widely spread throughout the world [22]. In Asia and in
China, ST239 accounted for 97% of nosocomial MRSA
infections [23]. ST239-MRSA III was also the major
clone found in our study. Staphylococcal protein A
(SpA) is a cell wall anchored virulence factor [24]. Our
research shows that most strains with RIF-R S. aureus
belong to ST239-MRSAIII-spa t030, a situation in ac-
cordance with Chen et al. [25]. Their research showed
t030 was up to 89.6% of MRSA in Peking Union Medical
College Hospital (PUMCH) in 2002. In addition, t030
was also found to be rifampicin resistant by Chen et al.,
which was the main difference with t037. Our results are
in line with these reports. These findings indicate that
ST239-MRSAIII-spa t030 strains, associated with high-
level rifampicin resistance, have spread in Anhui Provin-
cial Hospital. Therefore, bacterial resistance surveillance
and the control of hospital infections should take these
findings into consideration in order to prevent and limit
the spread of high-level rifampicin resistant S. aureus.
Conclusion
Most RIF-R MRSA isolates were high-level resistant in
our study. Rifampicin-resistance in S .aureus is closely
associated with mutations which occur in the rpoB gene.
ST239- MRSA III-spa t030 strains, which was associated
with the high-level rifampicin resistance, has spread in
Anhui Provincial Hospital.
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